N
PBYI icon

Natixis’s Puma Biotechnology PBYI Stock Holding History

Natixis’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-27,615
Closed -$351K – 896
2019
Q2 		$351K Buy
+27,615
New +$636K ﹤0.01% 644
2018
Q3 		– Sell
-9,532
Closed -$564K – 938
2018
Q2 		$564K Sell
9,532
-1,290
-12% -$74.8K ﹤0.01% 679
2018
Q1 		$736K Buy
10,822
+1,631
+18% +$122K ﹤0.01% 629
2017
Q4 		$909K Buy
9,191
+2,743
+43% +$307K 0.01% 515
2017
Q3 		$772K Buy
+6,448
New +$600K 0.01% 560

Other funds holding PBYI

PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Natixis's PBYI Position: Q3 2019 in Review

Natixis sold out of Puma Biotechnology (PBYI) in Q3 2019, closing a stake of 27,615 shares — an estimated $351K sold.

Natixis first reported a position in PBYI in Q3 2017 and held it in 5 quarters. The position peaked at $909K in Q4 2017. 144 funds tracked by Wall St. Rank hold PBYI as of Q3 2019.

  • Natixis reported no remaining Puma Biotechnology position as of Q3 2019 after selling out during the quarter.
  • Natixis sold 27,615 Puma Biotechnology shares in Q3 2019, an estimated $351K.
  • Natixis first reported a position in Puma Biotechnology in Q3 2017 and held it in 5 quarters.
  • Natixis's Puma Biotechnology position peaked at $909K in Q4 2017.
  • 144 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2019.

Based on Natixis's 13F filing for Q3 2019, filed 13 Nov 2019.